David Kirn - 08 Feb 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Signature
By: /s/ Scott Bizily as Attorney-in-fact David Kirn
Issuer symbol
FDMT
Transactions as of
08 Feb 2024
Transactions value $
-$2,495,822
Form type
4
Filing time
12 Feb 2024, 20:22:03
Previous filing
25 Jan 2024
Next filing
26 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Sale -$2.5M -92K -7.99% $27.13 1.06M 08 Feb 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.
F2 The transaction was executed in multiple trades in prices ranging from $26.75 to $27.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.